| Source: HalifaxProj(inhibit) |
| Type: |
| Akt1 is involved in cellular survival pathways, by inhibiting apoptotic processes; Akt2 is an important signaling molecule in the insulin signaling pathway. It is required to induce glucose transport. Inhibitors: -Curcumin: downregulate AKT phosphorylation and signaling. -Resveratrol -Quercetin: inhibit the PI3K/AKT pathway. -Epigallocatechin Gallate (EGCG) -Luteolin and Apigenin: inhibit AKT phosphorylation |
| 7691- | IP6, | Inositol Hexaphosphate Suppresses Growth and Induces Apoptosis in Prostate Carcinoma Cells in Culture and Nude Mouse Xenograft: PI3K-Akt Pathway as Potential Target |
| - | vitro+vivo, | Pca, | PC3 | - | in-vitro, | Pca, | C4-2B |
| 7699- | IP6, | IP6: From Seeds to Science—A Natural Compound’s Path to Clinical Promise |
| - | Review, | Var, | NA |
| 7704- | IP6, | Inositol hexaphosphate hydrolysate competitively binds to AKT to inhibit the proliferation of colon carcinoma |
| - | in-vitro, | CRC, | SW-620 |
| 8280- | ISL, | ISL Induces Apoptosis and Autophagy in Hepatocellular Carcinoma via Downregulation of PI3K/AKT/mTOR Pathway in vivo and in vitro |
| - | vitro+vivo, | HCC, | SMMC-7721 cell |
| 7750- | ISL, | Isoliquiritigenin in Breast Cancer: A Systematic Review of Its Preventive and Anti-metastatic Mechanisms |
| - | Review, | BC, | NA |
| 7745- | ISL, | Isoliquiritigenin inhibits colorectal cancer progression by targeting the FGFR4/FASN mediated lipid metabolism pathway |
| - | in-vitro, | CRC, | NA |
| 7746- | ISL, | Isoliquiritigenin Inhibits the Growth of Colorectal Cancer Cells through the ESR2/PI3K/AKT Signalling Pathway |
| - | vitro+vivo, | CRC, | SW480 | - | vitro+vivo, | CRC, | HCT116 |
| 7761- | ISL, | Targeting digestive system cancers with isoliquiritigenin: a comprehensive review of antitumor mechanisms |
| - | Review, | Var, | NA |
| 7763- | ISL, | Harnessing Liquiritigenin: A Flavonoid-Based Approach for the Prevention and Treatment of Cancer |
| - | Review, | Var, | NA |
| 7781- | ISL, | Perspectives on the Role of Isoliquiritigenin in Cancer |
| - | Review, | Var, | NA |
| 9254- | ISO, IH, | Isorhamnetin: what is the in vitro evidence for its antitumor potential and beyond? |
| - | Review, | Var, | NA |
| 9253- | ISO, IH, | Progress in the antitumor molecular mechanisms of Isorhamnetin |
| - | Review, | Var, | NA |
| 9252- | ISO, IH, | Isorhamnetin: Reviewing Recent Developments in Anticancer Mechanisms and Nanoformulation-Driven Delivery |
| - | Review, | Var, | NA |
| 9251- | ISO, IH, | Advances in Isorhamnetin Treatment of Malignant Tumors: Mechanisms and Applications |
| - | Review, | Var, | NA |
| 9239- | ISO, IH, | Isorhamnetin suppresses colon cancer cell growth through the PI3K‑Akt‑mTOR pathway |
| - | in-vitro, | CRC, | HT-29 | - | in-vitro, | CRC, | HCT116 | - | in-vitro, | Colon, | SW480 |
| 9244- | ISO, IH, | Isorhamnetin inhibits bladder cancer progression by mediating glycolysis through targeting the SRC/PI3K/Akt axis |
| - | in-vitro, | Bladder, | 5637 |
| 9242- | ISO, IH, | Isorhamnetin Induces Melanoma Cell Apoptosis via the PI3K/Akt and NF- κ B Pathways |
| - | vitro+vivo, | Melanoma, | B16-BL6 |
| - | in-vitro, | Pca, | DU145 | - | in-vitro, | Pca, | PC3 |
| 9240- | ISO, IH, | Isorhamnetin inhibits cell proliferation and induces apoptosis in breast cancer via Akt and mitogen‑activated protein kinase kinase signaling pathways |
| - | in-vitro, | BC, | NA |
| 7730- | isoFl, | Anticancer Potential of Isoflavones: A Narrative Overview of Mechanistic Insights and Experimental Evidence from the Past Ten Years |
| - | Review, | Var, | NA |
| 7855- | isoO, | Isoorientin induces apoptosis and autophagy simultaneously by reactive oxygen species (ROS)-related p53, PI3K/Akt, JNK, and p38 signaling pathways in HepG2 cancer cells |
| - | in-vitro, | Liver, | HepG2 | - | in-vitro, | Nor, | HL7702 |
| 7854- | isoO, | Isoorientin induces apoptosis through mitochondrial dysfunction and inhibition of PI3K/Akt signaling pathway in HepG2 cancer cells |
| - | in-vitro, | Liver, | HepG2 |
| 7853- | isoO, | Natural flavonoid isoorientin and its anticancer mechanisms: a systematic review |
| - | Review, | Var, | NA |
| 7876- | isoO, | Isoorientin exerts a protective effect against 6-OHDA-induced neurotoxicity by activating the AMPK/AKT/Nrf2 signalling pathway |
| - | in-vitro, | Nor, | NA |
| 7873- | isoO, | Isoorientin attenuates doxorubicin-induced cardiac injury via the activation of MAPK, Akt, and Caspase-dependent signaling pathways |
| - | in-vitro, | Liver, | HepG2 | - | in-vitro, | CRC, | HT-29 | - | in-vitro, | Lung, | A549 |
| 7872- | isoO, | Isoorientin ameliorates H2O2-induced apoptosis and oxidative stress in chondrocytes by regulating MAPK and PI3K/Akt pathways |
| - | in-vivo, | Arthritis, | NA |
| - | vitro+vivo, | AD, | PC12 |
| 7869- | isoO, | Apoptosis induction and inhibition of invasion and migration in gastric cancer cells by Isoorientin studied using network pharmacology |
| - | in-vitro, | GC, | HGC27 |
| 7797- | ISQ, | Isoquercitrin Suppresses Esophageal Squamous Cell Carcinoma (ESCC) by Inducing Excessive Autophagy and Promoting Apoptosis via the AKT/mTOR Signaling Pathway |
| - | vitro+vivo, | ESCC, | KYSE-510 | - | in-vitro, | ESCC, | KYSE450 |
| 7795- | ISQ, | The Flavonol Isoquercitrin Promotes Mitochondrial-Dependent Apoptosis in SK-Mel-2 Melanoma Cell via the PI3K/AKT/mTOR Pathway |
| - | in-vitro, | Melanoma, | SK-MEL-28 | - | in-vitro, | Nor, | HaCaT |
| 7793- | ISQ, | Apoptosis triggered by isoquercitrin in bladder cancer cells by activating the AMPK-activated protein kinase pathway |
| - | in-vitro, | Bladder, | T24/HTB-9 |
| 9194- | ITCs, | SFN, | BITC, | Erucin and benzyl isothiocyanate suppress growth of late stage primary human ovarian carcinoma cells and telomerase activity in vitro |
| - | in-vitro, | Ovarian, | NA |
| 9173- | ITCs, | SFN, | Dietary isothiocyanates and anticancer agents: exploring synergism for improved cancer management |
| - | Review, | Var, | NA |
| 9191- | ITCs, | AITC, | BITC, | PEITC, | SFN | Molecular Targets of Isothiocyanates in Cancer: Recent Advances |
| - | Review, | Var, | NA |
| 2180- | itraC, | Repurposing Drugs in Oncology (ReDO)—itraconazole as an anti-cancer agent |
| - | Review, | Var, | NA |
| 7999- | itraC, | Itraconazole-Induced Inhibition on Human Esophageal Cancer Cell Growth Requires AMPK Activation |
| - | vitro+vivo, | ESCC, | NA |
| 8009- | itraC, | Itraconazole exerts its anti-melanoma effect by suppressing Hedgehog, Wnt, and PI3K/mTOR signaling pathways |
| - | vitro+vivo, | Melanoma, | SK-MEL-28 | - | vitro+vivo, | Melanoma, | A375 |
| 8012- | itraC, | Effects and mechanism of itraconazole on prostate cancer PC-3 cell apoptosis |
| - | in-vitro, | Pca, | PC3 |
| 8019- | itraC, | Itraconazole Inhibits AKT/mTOR Signaling and Proliferation in Endometrial Cancer Cells |
| - | in-vitro, | Endo, | AN3CA | - | in-vitro, | Endo, | HEC-1A | - | in-vitro, | Endo, | HEC-50B | - | in-vitro, | Endo, | SNG-II |
| 8031- | IVM, | Antiparasitic agents in oncology: Innovative mechanisms, emerging evidence and clinical potential in cancer treatment |
| - | Review, | Nor, | NA |
| 8029- | IVM, | Ivermectin in Cancer Treatment: Should Healthcare Providers Caution or Explore Its Therapeutic Potential? |
| - | Review, | Var, | NA |
| 8028- | IVM, | Ivermectin as an Alternative Anticancer Agent: A Review of Its Chemical Properties and Therapeutic Potential |
| - | Review, | Var, | NA |
| 8027- | IVM, | Progress in Understanding the Molecular Mechanisms Underlying the Antitumour Effects of Ivermectin |
| - | Review, | Var, | NA |
| 8020- | IVM, | Ivermectin induces PAK1-mediated cytostatic autophagy in breast cancer |
| - | vitro+vivo, | BC, | NA |
| 8047- | IVM, | The multitargeted drug ivermectin: from an antiparasitic agent to a repositioned cancer drug |
| - | Review, | Var, | NA |
| 8040- | IVM, | Ivermectin, a potential anticancer drug derived from an antiparasitic drug |
| - | Review, | Var, | NA |
| 8039- | IVM, | Ivermectin-Induced Apoptotic Cell Death in Human SH-SY5Y Cells Involves the Activation of Oxidative Stress and Mitochondrial Pathway and Akt/mTOR-Pathway-Mediated Autophagy |
| - | in-vitro, | neuroblastoma, | SH-SY5Y |
| 8049- | IVM, | Ivermectin Induces Cytostatic Autophagy by Blocking the PAK1/Akt Axis in Breast Cancer |
| - | vitro+vivo, | BC, | NA |
| 7912- | IVT, | Isovitexin modulates autophagy in Alzheimer’s disease via miR-107 signalling |
| - | in-vivo, | AD, | NA |
| 7896- | IVT, | VT, | Molecular targets of vitexin and isovitexin in cancer therapy: a critical review |
| - | Review, | Var, | NA |
Query results interpretion may depend on "conditions" listed in the research papers. Such Conditions may include : -low or high Dose -format for product, such as nano of lipid formations -different cell line effects -synergies with other products -if effect was for normal or cancerous cells
Filter Conditions: Pro/AntiFlg:% IllCat:% CanType:% Cells:% prod#:% Target#:4 State#:% Dir#:%
wNotes=0 sortOrder:rid,rpid